Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature

Solid organ transplant recipients on long-term immunosuppressive medication are at increased risk of developing malignancy, and treatment of advanced cancers with angiogenesis inhibitors in this context has not been widely studied. We present a case of recurrent high-grade serous ovarian carcinoma t...

Full description

Bibliographic Details
Main Authors: Lawrence Kasherman, Jeffrey Doi, Katherine Karakasis, Jeffrey Schiff, Abhijat Kitchlu, Stephanie Lheureux, Amit M. Oza
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Current Oncology
Subjects:
bevacizumab
vascular endothelial growth factor
angiogenesis inhibitor
transplant
proteinuria
nephrotoxicity
Online Access:https://www.mdpi.com/1718-7729/28/1/64
Description
Summary:Solid organ transplant recipients on long-term immunosuppressive medication are at increased risk of developing malignancy, and treatment of advanced cancers with angiogenesis inhibitors in this context has not been widely studied. We present a case of recurrent high-grade serous ovarian carcinoma treated with paclitaxel and bevacizumab in the context of prior renal transplantation where the patient responded well to treatment with controlled toxicities, discussing the potential for increased rates of adverse events and drug interactions in this select population.
ISSN:1198-0052
1718-7729

Similar Items